Summary

The South & Central America epilepsy drugs market was valued at US$ 458.85 million in 2022 and is expected to reach US$ 585.38 million by 2030; it is estimated to grow at a CAGR of 3.1% from 2022 to 2030.

Several Epilepsy Drugs Nearing Patent Expiration Fuels South & Central America Epilepsy Drugs Market

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

South & Central America Epilepsy Drugs Market Overview

The South & Central America epilepsy drugs market is segmented into the Brazil, Argentina, and the Rest of South & central America. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.

South & Central America Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Epilepsy Drugs Market Segmentation

The South & Central America epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the South & Central America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the South & Central America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the South & Central America epilepsy drugs market is segmented Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd, are some of the leading companies operating in the South & Central America epilepsy drugs market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
5. South & Central America Epilepsy Drugs Market - Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market - South & Central America Market Analysis
6.1 Overview
6.2 South & Central America Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030
7. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment
7.1 Overview
7.2 South & Central America Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 South & Central America Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis
9.1 South & Central America Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
9.1.1 South & Central America Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
9.1.1.1 Brazil: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 Brazil: South & Central America Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.1.1.1.3 Brazil: South & Central America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.1.4 Brazil: South & Central America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Argentina: South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Argentina: South & Central America Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.1.1.2.3 Argentina: South & Central America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.2.4 Argentina: South & Central America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 Rest of South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Rest of South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 Rest of South & Central America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.3.4 Rest of South & Central America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Epilepsy Drugs Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Pfizer Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Abbott Laboratories
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sanofi SA
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Teva Pharmaceutical Industries Ltd
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Alkem Laboratories Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms